Drug Trial Radar · NCT02243293
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
Last checked: Nov 20, 2026Latest source record: Jul 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
694
Actual
Start
Sep 19, 2014
Primary completion
Oct 25, 2016
Study completion Feb 23, 2017
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase 2/3, open-label, multipart, multicenter study was to evaluate the efficacy, and safety of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) in chronic HCV genotype 2 (GT2-), genotype 3 (GT3-), genotype 4 (GT4), genotype 5 (GT5-), or genotype 6 (GT6-) infected participants with or without cirrhosis.
Conditions
- Chronic Hepatitis C
- Hepatitis C Virus
Interventions
ABT-493Drug
Tablet
ABT-530Drug
Tablet
ribavirin (RBV)Drug
Tablet
ABT-493/ABT-530Drug
Tablet; ABT-493 co-formulated ABT-530
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)Time frame: 12 weeks after the last actual dose of study drug
- Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical ControlTime frame: 12 weeks after the last actual dose of study drug
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.